Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
11.12
+0.32 (2.96%)
At close: Jun 8, 2026, 4:00 PM EDT
11.00
-0.12 (-1.08%)
After-hours: Jun 8, 2026, 7:58 PM EDT
Biohaven Employees
Biohaven had 274 employees as of December 31, 2025. The number of employees increased by 18 or 7.03% compared to the previous year.
Employees
274
Change (1Y)
18
Growth (1Y)
7.03%
Revenue / Employee
n/a
Profits / Employee
-$2,363,785
Market Cap
1.67B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 274 | 18 | 7.03% |
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Ascentage Pharma Group International | 767 |
| Novavax | 749 |
| Agios Pharmaceuticals | 540 |
| Nuvation Bio | 307 |
| uniQure | 221 |
| Innoviva | 159 |
| Taysha Gene Therapies | 99 |
BHVN News
- 7 days ago - Biohaven initiates first-in-human dosing for BHV-8100 - TheFly
- 7 days ago - Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation - PRNewsWire
- 12 days ago - Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy - TheFly
- 12 days ago - Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy - PRNewsWire
- 13 days ago - Biohaven reports data from selective Kv7.2/7.3 channel activator program - TheFly
- 13 days ago - Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile - PRNewsWire
- 26 days ago - Biohaven price target lowered to $18 from $21 at Morgan Stanley - TheFly
- 4 weeks ago - Biohaven price target lowered to $22 from $23 at RBC Capital - TheFly